Vanqua Bio

Small Molecules Targeting Neuro Indications

Also RD Parkinson's, Lewy body dementia; 2 additional undisclosed programs RD Alzheimer's, Parkinson's, neurodegenerative diseases

Vanqua Bio utilizes our knowledge of lysosomal biology and the immune system, along with an iPSC-derived neuronal cell screening platform to find treatments for neurodegenerative diseases. They aim to develop disease-modifying therapies rather than treating symptoms, as current neurodegenerative treatments do. This approach has the potential to slow or stop the progression of these neurological diseases like Alzheimer’s and Parkinson’s disease. Vanqua is targeting lysosomal function and the complement pathway of the immune system to achieve their goals, both having aberrant activity in various neurodegenerative diseases. These therapeutics hold promise for those with debilitating neurological disorders that currently have limited treatment options.